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ABSTRACT 
 
Prediction of Response to Escitalopram Across Multiple Outcomes in Older Adult GAD 
Patients 
 
Caroline M. Ciliberti 
 
Anxiety disorders are common in late-life and have detrimental effects of health and 
well-being (Stanley, Diefenbach, & Hopko, 2003; Wetherell et al., 2004).  Generalized 
Anxiety Disorder (GAD) is the most common anxiety disorder in late-life (Beekman et 
al., 1998).  Beyond the diagnostic symptoms, older adults with anxiety disorders may 
present with a variety of physical symptoms (Palmer, Jeste, & Sheikh, 1997).  As a result, 
GAD is a heterogeneous disorder. Empirically-supported treatments are available for late-
life GAD, but little is known about how people with different constellations of presenting 
symptoms respond to treatment, and whether they differ according to the way in which 
improvement is measured.  The present study aimed to identify which presenting 
symptoms differentiated older adults with GAD from those without and how those 
symptoms predicted outcome across several domains of response.  Participants were 
enrolled in a trial testing the efficacy of escitalopram for treatment of late-life GAD.  One 
hundred and seventy-seven older adults with GAD and 41 older adults with no diagnosis 
participated.  One hundred percent of the cases were correctly classified on the basis of 
the ―Anxious Mood‖ and ―Tension‖ SIGH-A items.  A subset of participants with GAD 
who had been randomly assigned to received escitalopram and had completed 12 weeks 
of blinded treatment were further analyzed.  Neither ―Anxious Mood‖ nor ―Tension‖ 
significantly predicted outcome in any domain.  However, baseline scores on several of 
the outcome measures accounted for a significant amount of variance in week 12 scores, 
with lower scores being associated with better outcomes.  These results indicate that 
baseline scores are the best predictors of outcome, and could have implications for 
treatment of GAD in late-life. 
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Prediction of Response to Escitalopram Across Multiple Outcomesin Older Adult GAD Patients 
 
Anxiety Disorders are common in late life, affecting 10.2% of older adults (Beekman et 
al., 1998). Despite their prevalence, anxiety disorders are often under-identified and under-
diagnosed among older adults (Harman, Rollman, Hanusa, Lenze, & Shear, 2002).  There are 
several challenges to detecting and diagnosing anxiety disorders among older adults that may 
account for this.  Most screening instruments were developed for use with younger adults and 
may be inappropriate for use with older adults.  Older adults may differ from younger adults in 
how they report their symptoms. Specifically, older adults are more likely to underreport 
symptoms of psychological distress (Tweed, Blazer, & Ciarlo, 1992), and may report different 
symptoms than younger adults, and are less likely than younger adults to report worthlessness 
associated with anxiety (Shapiro, Roberts, & Beck, 1999).   Further, older adults tend to be more 
exact when describing negative affective states (Shapiro et al., 1999), emphasizing the 
importance of capturing the lexicon of older adults when screening for anxiety disorders.   
There are conflicting findings about somatic presentations of anxiety in older adults. For 
example, Christensen and colleagues (1999) found that older adults reported fewer somatic 
symptoms of anxiety on assessment instruments, such as headaches and physical tension, in 
comparison to younger adults.  In contrast, some studies have found that older adults report more  
somatic symptoms than younger adults (Spar & LaRue, 1990), and still others have found no 
difference in the reporting of somatic symptoms between age groups (Stanley et al., 2003).   
Further complicating diagnosis, anxiety disorders frequently are comorbid with another 
Axis I disorder, or a physical disorder among older adults.  Perhaps due in part to an overlap in 
diagnostic symptoms, 27.5% of older adults diagnosed with major depression are also diagnosed 
with an anxiety disorder (Lenze et al., 2000).  People with anxiety disorders also have more 
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physical comorbities, and greater physical disability than those without (Brenes et al., 2005; de 
Buers et al., 1999; Palmer, Jeste, & Sheikh, 1997).  Palmer and colleagues (1997) outline several 
possible factors that may explain this co-occurrence.  First, both physical illness and anxiety are 
common in older adults, and thus co-occur.  Second, some symptoms of anxiety are somatic.  For 
example, palpitations and sweating may be manifestations of anxiety but are sometimes 
interpreted as signs of physical illness.  It is also the case that anxiety might result from the stress 
of having a physical illness.  Finally, some physical illnesses (e.g., hyperthyroidism) may present 
as anxiety, and some medications used to treat physical illnesses may cause anxiety as a side 
effect (Palmer et al., 1997). These factors make detecting anxiety in older adults challenging. 
   As a result of these age-related differences in the experience and presentation of anxiety 
symptoms, the current diagnostic criteria may not adequately capture the experience and 
presentation of anxiety in older adults, leading to under-recognition.  Thus, older adults may go 
undiagnosed with anxiety symptoms, resulting in a lifestyle associated with diminished well 
being, increased use of health services, more severe depression, and poorer social functioning (de 
Buers et al., 1999; Lenze et al., 2001).   
Of the anxiety disorders, Generalized Anxiety Disorder (GAD) is the most common 
among older adults, affecting 7.3% of community dwelling older adults (Beekman et al., 1998).  
GAD is associated with poorer quality of life (Bourland et al., 2000; Porensky et al., 2009; 
Stanley, Diefenbach, & Hopko, 2003; Wetherell et al., 2004), and worse perceptions of mental 
and physical health (Stanley et al., 2003) than of individuals without this disorder.  According to 
the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV; APA, 1994) 
criteria, GAD is characterized by excessive and difficult to control worry about multiple events, 
occurring on most days for a minimum of 6 months.  The worry is accompanied by three or more 
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of the following six symptoms:  restlessness or feeling edgy, being easily fatigued, trouble 
concentrating or mind going blank, irritability, muscle tension, and sleep disturbance.  However, 
the proposed criteria for the 5th edition of the DSM focus more on distress and impairment due to 
worry, requiring excessive and interfering worry and either restlessness or muscle tension to 
receive a diagnosis of GAD (APA, 2010).  These proposed changes put more emphasis on the 
core symptom of GAD: worry.  Many people with GAD expend a disproportionate amount of 
time worrying about everyday situations, and find it difficult to stop worrying.  In addition to the 
diagnostic symptoms, some people with GAD experience an increase in somatic symptoms, such 
as upset stomach and sweating (APA, 1994).  Though some worries (e.g., worries about family, 
and health of a loved one) seem to be common among all older adults, certain topics of worry 
have been shown to differentiate older adults with GAD from those without GAD (Wetherell, Le 
Roux, & Gatz, 2003). These topics include worry about small matters, finances, personal health, 
and social matters (Wetherell et al., 2003).  However, only 13.3% of patients with GAD present 
for treatment with anxiety as their primary complaint (Wittchen et al., 2002).  Instead, many 
present with physical symptoms (Flint, 2005; Wittchen et al., 2002).  Because of the complicated 
nature of the link between somatic symptoms and anxiety in older adults, it is often difficult for 
providers to determine whether these presenting somatic symptoms are actual symptoms of GAD 
or a result of some physical illness.  Wetherell and colleagues (2003) examined the associated 
diagnostic symptoms among older adults with GAD and older adults with no DSM diagnosis.  
Older adults with GAD were more likely than members of the control group to endorse trouble 
sleeping, muscle tension, fatigue, restlessness, and irritability.   Sleep disturbance and muscle 
tension are especially salient among older adults with GAD.  However, trouble concentrating did 
not distinguish those with GAD from the control group (Wetherell et al., 2003).  Beck, Stanley, 
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and Zebb (1999) also compared older adults with GAD to older adults with no DSM diagnosis.  
They found older adults with GAD differed in regard to categories of self-reported symptoms 
(i.e., tension and anxiety, somatic symptoms, and agitated behavior).  
 In addition to the diagnostic and presenting symptoms of GAD discussed above, 
neurobiological markers have been proposed for the identification of GAD.  Some hypothesize 
that depression and anxiety are characterized by hypothalamic pituitary adrenal (HPA) axis 
dysregulation in the brain, resulting in abnormal levels of the stress hormone, cortisol (Mantella 
et al., 2008).   Researchers can make inferences about HPA-axis functioning by measuring the 
production of cortisol.  Researchers often measure salivary cortisol levels because it is a 
minimally invasive technique, and levels of salivary cortisol correspond with levels of serum 
cortisol (Hansen, Garde, & Persson, 2008).  It is important to examine the neurobiology of older 
adults because it is possible that there are significant changes with age.  Studies of HPA axis 
activity in older adults have shown increases in activity associated with increased age (Van 
Caurter et al., 1996), and increases in mean levels of cortisol (Ferrari, Magri, Dori, Migliorati, 
Nescis, Molla, Fioravanti, & Solerte, 1995).  There is also evidence that HPA axis dysregulation 
may be linked to anxiety disorders in older adults.  More severe GAD, as measured by the Penn 
State Worry Questionnaire (PSWQ) and the GAD Severity Scale (GADSS; Shear, Belnap, 
Mazumdar, Houck, & Rollman, 2006), has been shown to be associated with higher levels of 
salivary cortisol (Mantella et al., 2008).  Further, older adults with anxiety disorders show higher 
levels of cortisol after being exposed to stressors than older adults without anxiety disorders 
(Chaudieu et al., 2008).   Chronic exposure to stress hormones may result in a host of negative 
outcomes, including impaired immune functioning and more cardiovascular stress. Such 
exposure also may contribute to the development of dementia (Mantella et al., 2008). 
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When appropriately identified, there are several pharmacological and psychosocial evidence-
based treatments available to older adults with GAD.    Historically, benzodiazepines were used 
to treat anxiety in older adults, but because of significant risks, most prescribers have moved 
towards the use of antidepressants as a first line treatment of GAD (Sheikh & Cassidy, 2000).  
The antidepressants venlafaxine ER and citalopram have been shown to be effective for treating 
GAD in older adults, resulting in improved clinical global impressions and improved Structured 
Interview Guide for the Hamilton Anxiety Scale (SIGH-A ; Shear et al., 2001) scores (Katz et al., 
2002; Lenze et al., 2005).  Escitalopram also has been shown to be effective for treating GAD, 
resulting in improvement in clinical global impressions, lower levels of worry (as measured by 
the PSWQ) and improved quality of life (as measured by the Short Form -36) (SF-36; Ware & 
Sherbourne, 1992).  Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that has been 
shown to be an effective treatment for GAD (Goodman, Bose, & Wang, 2005; Lenze, et al., 
2009).  In a pooled analysis of randomized controlled trials examining the efficacy of 
escitalopram in participants ranging from 18 to 80, escitalopram was shown to be well tolerated 
and effective at reducing post treatment Hamilton Anxiety Rating Scale scores (Goodman, Bose, 
& Wang, 2005).  Several psychosocial treatments also have been shown to be efficacious among 
older adults with GAD.  Relaxation training and cognitive-behavior therapy (CBT) have the most 
support for their efficacy in the treatment of GAD among older adults (Ayers, Sorrell, Thorp, & 
Wetherell, 2007).  A review by Ayers and colleagues (2007) found 9 studies supporting the use of 
CBT for treatment of GAD in older adults.  For example, Mohlman et al. (2003) found that older 
adults with GAD receiving CBT showed a greater reduction in GAD severity at 6 months follow 
up than those in a wait-list control group.  Stanley, Beck, and Glassco (1996) found that CBT 
treatment resulted in reduced anxiety, worry, and depression, as measured by GAD severity, the 
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PSWQ, the Hamilton Anxiety Scale, the Worry Scale (WS; Wisocki, Handen, & Morse, 1986), 
and the State Trait Anxiety Inventory – Trait (STAI-T; Spielberger, Gorsuch, & Lushene, 1970).  
Several of the studies discussed above used different strategies for measuring treatment 
response (e.g., a drop in scores on a measure of anxiety, a global rating of improvement, or a 
change in quality of life measures) and consequently used different definitions of response to 
determine whether an intervention was effective.  These outcome measures are certainly helpful, 
but they may not adequately depict response to treatment.   
Most of the research studies supporting both pharmacological and psychosocial 
treatments of GAD have measured improvement by examining changes in total scores on 
assessment instruments.  Few studies have performed a fine grained analysis of the qualitative 
changes in individual anxiety symptoms with treatment.  Lecrubier, Dolberg, Anderson, and 
Weiller (2008) examined qualitative changes in symptomatology with escitalopram treatment, by 
examining patterns of treatment changes in people with GAD, Major Depressive Disorder 
(MDD), and patients with mixed anxiety and depression.  Their work focused largely on 
describing treatment effects by retrospectively examining  the specific groups of symptoms that 
changed with treatment.  Stein, Anderson, and Goodman (2005) pooled 3 antidepressant 
treatment studies, and examined changes in the symptom clusters assessed on the SIGH-A 
among adults with GAD.  They found significant treatment effects for 7 of the 14 symptom 
clusters (anxious mood, tension, fears, insomnia, intellectual, depressed mood, and interview 
behavior).  Though both the Lecrubier and the Stein studies took a closer look at the specific 
qualitative changes of anxiety symptoms with treatment, neither study focused on older adults 
with GAD.  
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 In addition to examining changes with treatment, researchers have attempted to identify 
pre-treatment variables that predict outcome (See Tables 1 and 2 for summaries).  The ability to 
predict outcome based on pre treatment presentation may help providers make informed 
treatment decisions when planning patient care.  Predictors of treatment response have been 
explored for both psychosocial and pharmacological therapies for the treatment of a variety of 
anxiety disorders (e.g., panic disorder and GAD).  Some diagnostic symptoms (e.g., sleep 
disturbance) have also been shown to predict positive response to treatment, while others (e.g., 
restlessness) predict poorer outcomes (Pollack, Meoni, Otto, & Hackett, 2003).  A history of 
substance abuse has been shown to predict positive outcomes (Pollack et al., 2003), while recent 
benzodiazepine use has been shown to predict negative outcomes (DeMartinis, Rynn, Rickels, & 
Mandos, 2000).  Further, early improvement has been shown to be associated with better longer 
term outcomes (Rynn et al., 2006).  Older age has been shown to predict poorer treatment 
outcomes, as have certain baseline comorbidities, including the presence of a personality 
disorder (Seivewright, Tyrer, & Johnson, 1998).  Haby, Donnelly, Corry, and Vos (2006) found 
that treatment studies that included samples with greater severity had poorer outcomes than those 
that didn’t.  Other study-design variables, including waitlist control, were associated with poorer 
outcomes.  Durham, Allan, and Hackett (1997) found that being married was associated with 
more favorable outcomes, whereas marital stress was associated with poorer outcomes.  Further, 
comorbid diagnoses were also associated with poorer outcomes. 
Only one study has examined the factors that predict GAD treatment response in a sample 
of older adults.  Wetherell and colleagues (2005) pooled data from 3 psychotherapy treatment 
studies for older adults.  Outcome was measured using a Reliable Change Index, or RCI, for 
three measures:  the GAD severity rating, Hamilton Anxiety Rating Scale (HAM-A), and PSWQ.   
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The RCI is an outcome measure used to quantify treatment gains.  Better outcomes were 
associated with higher GAD severity at baseline, presence of Axis I comorbidity, and more 
frequent homework (Wetherell et al., 2005).     
In sum, several studies have examined demographic, psychiatric, and treatment variables 
that predict treatment response for GAD.  However, only one (Wetherell et al., 2005) has used a 
sample of older adults, and only one (Pollack et al., 2003) has examined the predictive value of 
the different symptom presentations.  There have been no studies that have examined the 
predictive value of common symptom presentations of anxiety, beyond those outlined by the 
DSM, and none that have examined the predictive value of symptom presentations in older 
adults.  It is possible that the DSM does not adequately capture the experience of anxiety in older 
adults, considering the diagnostic challenges discussed above.  Moreover, the DSM diagnostic 
symptoms are broad and vaguely worded (Brown & Barlow, 2009).  The threshold levels used to 
diagnose GAD are not based on empirical evidence, and are difficult to assess in clinical practice 
(Brown & Barlow, 2009).  Considering the unique presentations of anxiety in older adults, 
knowledge of how symptoms predict positive treatment outcome would be valuable.    
Treatment outcome researchers have defined response in different ways.  Some studies 
have relied on global measures of improvement, some on reduction in worry, and some on 
changes in physiological responses.  However, it is unclear how these response measures relate 
to each other, and how the course of treatment may differ according to how one defines response.  
Typically, researchers rely on one outcome measure, assessing one response mode, to determine 
the efficacy of an intervention.  Treatment studies of GAD frequently focus on either change 
scores on a single measure of anxiety (e.g., SIGH-A, HAMA,  PSWQ), or measures of global 
improvement (e.g., CGI).  However, some researchers (e.g., Barlow, 1981) have proposed that 
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statistically significant outcome measures typically used in research settings may have little 
practical significance for the patients.  Moreover, some have noted that there is a rift between 
research outcomes and clinically relevant patient care (Tunis, Stryer, & Clancy, 2003).  There 
may be little concordance between standard clinical measures, and clinically relevant 
improvement (Glasgow, Magid, Beck, Ritzwoller, & Estabrooks, 2005).   
In addition to measures of symptom severity, some advocate for collecting a broad range 
of outcome measures to determine the clinical relevance of a treatment.  Some authors have 
called for a ―patient-centered approach,‖ that relies on practical and relevant outcome measures 
such as quality of life, functional outcome, and satisfaction (Glasgow et al., 2005; Tunis et al., 
2003). The importance of examining multiple response modes, including motoric, cognitive, and 
physiological responses, has also been stressed for decades in the assessment literature (Eid & 
Diener, 2006; Hayes and O’Brien, 2000; Lang, 1968).  This is important, in part, because of the 
discordance between response modes, which is especially salient in anxiety disorders (e.g., Glass 
& Arnkoff, 1989; Lang, 1968).  For example, a person’s cognitive response to a feared stimulus 
(e.g., ―I feel scared.‖) may not necessarily match his or her physiological response (e.g., 
increased levels of salivary cortisol, increased blood pressure).  Similarly, self-reported fear may 
not match a person’s actions or physiological response.  Such findings also suggest variability in 
patterns of response to arousing stimuli across individuals (Lacey, Bateman, & Van Lehn, 1953). 
Thus, some outcome measures will more accurately reflect an individual’s response to arousing 
stimuli than others.  In summary, these findings reinforce the importance of examining treatment 
outcome comprehensively, and certainly beyond the usual measures of anxiety or global 
improvement in older adults.  
 
10 
 
Statement of the Problem 
Anxiety disorders are common among older adults, affecting up to 10.2% of older adults 
(Beekman et al., 1998).  Generalized Anxiety Disorder (GAD) is the most common of the 
anxiety disorders among older adults, affecting 7.3% of those in the community (Beekman et al., 
1998).  However, GAD often goes underreported and undertreated in older adults (Harman et al., 
2002), in part because of some unique challenges to diagnosis in this population (Lenze et al., 
2000; Palmer et al., 1997).  For example, older adults may present with different symptoms than 
younger adults (Christensen et al., 1999; Shapiro et al., 1999; Spar & LaRue,1990).  Further, 
frequent medical and psychiatric comorbidities may complicate the diagnostic picture due to 
overlap in symptoms (Lenze et al., 2000; Palmer et al., 1997). This under-detection is 
problematic because GAD is associated with poorer quality of life (Bourland et al., 2000; 
Porensky et al., 2009; Stanley et al., 200; Wetherell et al., 2004;), and worse perceptions of 
mental and physical health (Stanley et al., 2003) among older adults. Moreover, GAD may be 
associated with abnormal HPA-axis functioning, and thus elevated levels of cortisol, which may 
put older adults with GAD at risk for more health problems, including dementia (Beaudreau, S. 
& O’Hara, R., 2008; Chaudieu et al., 2008; Mantella et al., 2008; Van Cauter et al., 1996).   
Researchers have attempted to identify potential predictors of treatment outcome, 
including demographic, psychiatric, and treatment variables (See Tables 1 and 2 for a summary). 
The identification of patient variables that can predict treatment outcome in older adults with 
GAD could have significant clinical and research implications. For example, knowledge of 
symptom presentations that predict positive treatment outcomes with particular treatments could 
guide providers when making treatment choices.   
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Because older adults may present with different symptoms of anxiety than younger adults 
(Christensen et al., 1999; Shapiro et al., 1999; Spar & LaRue,1990), the symptoms that predict 
treatment success for them may also differ from those that predict success in younger adults.  
Only one study has examined the predictive value of baseline symptoms and treatment variables 
for treatment outcome in a sample of older adults.  Using a Reliable Change Index, or RCI, for 
three measures (GAD severity rating using Anxiety Disorders Interview Schedule for Adults 
(ADIS-IV; Brown, DiNardo, & Barlow, 1994) ratings, HAMA scores, and PSWQ scores), 
Wetherell and colleagues found that better outcomes were associated with higher GAD severity 
at baseline, presence of Axis I comorbidity, and more frequent homework (Wetherell et al., 
2005). However, this study relied on total scores from their clinical measures and various 
treatment variables, rather than specific presenting symptoms, to predict outcome.   Although 
helpful, such studies do not provide a fine-grained analysis of the presenting symptoms that are 
associated with positive outcomes.     
Because older adults may present with different symptoms of anxiety than their younger 
counterparts (Christensen et al., 1999;  Shapiro et al., 1999) it may be useful to take a broader 
look at the symptoms that predict response, beyond the DSM criteria. For example, no studies 
have examined the predictive value of somatic manifestations of anxiety (e.g., cardiovascular 
symptoms and gastrointestinal distress) on treatment outcome.   
  For those older adults whose anxiety disorders are identified, effective pharmacological 
(Lenze et al., 2009; Sheikh & Cassidy, 2000) and psychosocial (see Ayers et al., 2007 for a 
review) treatments are available. Though there have been several promising treatment studies, 
both examining pharmacological and psychosocial treatments, there is no consistently used 
treatment outcome measure and no consensus on what outcome measure should be used. Some 
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of the studies discussed above defined treatment outcome as a reduction of worry (e.g., Stanley 
et al., 1996), while others defined response as a reduction in presenting symptoms of anxiety 
(e.g., Lenze et al., 2005).   Still others defined response as reduction in GAD severity (e.g., 
Mohlman et al., 2003), improved quality of life (e.g., Lenze et al., 2009; Stanley et al., 1996), or 
overall global improvement (e.g., Lenze et al., 2009).  Most studies examined some combination 
of these response measures, but focused outcome on one measure of response.  In addition to 
traditional outcome measures of symptom severity and morbidity, some have advocated the use 
of multiple measures of outcome across different domains (Lang, 1968), and the use of measures 
that have practical clinical significance (e.g., Glasgow et al., 2005; Tunis et al., 2003).  Little 
research has examined the ways in which treatment response varies according to how outcome is 
measured, and whether a positive outcome in one domain is associated with a positive outcome 
in others (e.g., is a reduction in worry associated with an improvement in quality of life?).  It is 
possible the people with different constellations of presenting symptoms respond to treatment in 
different ways.  However, most researchers haven’t specifically identified who improves from 
what treatment, and in which ways they benefit.   
 In sum, researchers have identified predictors of treatment response among younger 
adults.  However, only one study has examined predictors in older adults (Wetherell et al., 2005), 
and only one study has examined the predictive power of specific symptom presentations, 
beyond DSM criteria, in a sample of young adults (Pollack et al., 2003).  We lack a clear picture 
of the value of the manifestations of anxiety, beyond the symptoms represented by the DSM-IV 
criteria, for predicting treatment response with older adults.  Moreover, the value of these 
predictors appears to vary depending upon how researchers have defined treatment response in 
each of the outcome studies. It is possible that the course of treatment, and treatment 
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effectiveness may vary according to how response is measured.  Previous studies typically have 
not employed outcome measures that examine change across different response modes. 
The present study was designed to address two objectives.  The first objective was to 
identify  presenting symptoms that differentiate older adults with GAD from those without GAD.  
The second objective was to determine which of those symptoms were predictive of treatment 
response, and how the symptoms predicted response for each of several different outcome 
measures.  To address the first objective, the current study examined the value of baseline levels 
of common presenting symptoms of GAD, as measured by SIGH-A items, in their ability to 
discriminate older adults with GAD from older adults without GAD. Using the baseline levels of 
the symptoms that differentiated older adults with GAD from those without, the current study 
addressed the second objective by examining the ability of these symptoms to predict treatment 
outcome in a sample of older adults with GAD receiving escitalopram.  The SIGH-A is 
comprised of 14 clusters of common presenting symptoms (anxious mood, tension, fears, 
insomnia, concentration, depressed mood, somatic muscular, somatic sensory, cardiovascular, 
respiratory, gastro-intestinal, genitor-urinary, autonomic, and behavior).  The current study  
examined the extent to which the baseline levels of symptom clusters that differentiated 
individuals with GAD from those without predicted successful treatment outcome as measured 
by the PSWQ scores, SF-36 quality of life scores (Mental and Physical components), global 
improvement scores, and cortisol levels.    
 
Method 
Participants 
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One hundred and seventy-seven participants, aged 60 and older, were recruited between the years 
2004 and 2008 for the parent study: a double-blind placebo controlled medication treatment 
study of the efficacy of escitalopram for the treatment of generalized anxiety disorder in older 
adults at the University of Pittsburgh Medical Center (Lenze et al., 2009).  Participants were 
recruited from primary care clinics, specialty medical care clinics, mental health clinics, and 
community advertisement.  Most of the participants were Caucasian (82%), and female (67.2%).  
Nearly one-quarter (24.8%) of the participants had a current diagnosis of a depressive disorder, 
and 20.9% had a diagnosis of a comorbid anxiety disorder, other than GAD.  All participants 
received one hundred dollars and study medication at no cost. 
Each participant was assessed using the Structured Clinical Interview for DSM Disorders 
(SCID; First, Spitzer, Gibbon, & Williams, 2002), and met criteria for a principal diagnosis of 
GAD, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV; APA, 1994).  Each participant scored 17 or higher on the SIGH-A, indicating 
clinically significant levels of anxiety.  Participants with active suicidal ideation, drug or alcohol 
abuse or dependence in the previous 6 months, a lifetime prevalence of psychosis or bipolar 
disorder, dementia, medical instability, or current psychotherapy, antidepressant, or anxiolytic 
treatment were excluded from the study (Lenze et al., 2009).      
To examine variables that predict treatment response to escitalopram, a subset of 
participants was examined.  Of the 177 participants who were randomized into the parent study, 
70 participants were randomized to escitalopram and completed 12 weeks of blinded treatment.  
Because researchers for the parent study did not begin collecting salivary cortisol samples at the 
outset of the study, salivary cortisol data are not available for some participants.  Of those 70 
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participants who were randomized to escitalopram and completed 12 weeks of treatment, only 23 
collected both baseline and week 12 samples of salivary cortisol.   
Forty-one control participants were also recruited.  Control participants had no SCID 
diagnosis.  As with participants in the active group, control participants with active suicidal 
ideation, a lifetime prevalence of dementia, medical instability, or current psychotherapy, 
antidepressant, or anxiolytic treatment were excluded from the study.        
Materials 
Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A; Shear et al., 
2001).  The Structured Interview Guide for the Hamilton Anxiety Rating Scale, or SIGH-A, is a 
14-item structured interview based on the Hamilton Rating Scale (HAMA; Hamilton, 1959) that 
is used to measure anxiety (See Appendix A). The items cover a range of psychological, 
physiological, and behavioral manifestations of anxiety.  Each item is rated on a scale from 0 to 
4, with higher scores indicating increased duration, distress, and impairment.  The HAMA is 
widely used to assess anxiety and has been validated for use with older adults (Beck, Stanley, & 
Zebb, 1999).  The HAMA has been shown to demonstrate good internal consistency (α = .77) 
among participants with GAD (Beck et al., 1999).  Further, it had good discriminant validity, 
correctly classifying 98% of older adults with GAD, and 100% of older adult controls (Beck et 
al., 1999).  The SIGH-A was developed by Shear and colleagues (2001) from the HAMA.  The 
SIGH-A offers more detailed instructions for administration, and clearer anchor points for rating.  
Though not tested in older adults, the SIGH-A demonstrates good internal consistency when 
tested over two days in a sample of adults with GAD (α = .79; Shear et al., 2001).  SIGH-A 
scores were also correlated with HAMA scores in a sample of adults aged 18 and older with 
GAD (r= 0.70 on day one, r= 0.72 on day two) (Shear et al., 2001).   The SIGH-A is organized 
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into 14 clusters of symptoms: anxious mood, tension, fears, insomnia, concentration, depressed 
mood, somatic muscular, somatic sensory, cardiovascular, respiratory, gastro-intestinal, genitor-
urinary, autonomic, and behavior.    Each cluster has a structured list of questions about various 
symptoms that fall under the broader category of the cluster.  The interviewer inquires about the 
presence of each symptom, then rates the whole cluster on a scale from 0-4 based on the 
frequency and severity of the collection of symptoms (See Appendix A).  The current study 
recorded the ―yes/ no‖ dichotomous response to each symptom under each category, to be able to 
have a more detailed picture of the experience of anxiety in older adults. 
 Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990). The PSWQ is a 16-item 
self-report questionnaire used to assess worry (See Appendix B). Each item is rated on a scale 
from 1 (not at all typical) to 5 (very typical).  Higher scores indicate higher levels of worry. In a 
sample of older adults, moderate correlations were observed between the PSWQ and other 
measures of anxiety, including the Worry Scale (WS;  r=.54, p<.01), the original Fear 
Questionnaire (FQ-A; r= .36), and the modified Fear Questionnaire (FQ-F; r=.30. , supporting  
convergent validity (Stanley, Novy, Bourland, Beck, & Averill, 2001).  Test-retest reliability of 
the PSWQ among older adults has been shown to be moderate (r = .54; Stanley et al., 2001). 
Short Form 36 Health Survey Questionnaire (SF-36; Ware & Sherbourne, 1992).  The 
SF-36 is a 36-item self-report measure of health that measures health across 8 dimensions:  
physical functioning, social functioning, role limitations, mental health, vitality, pain, general 
health perception, and health change (see Appendix C).  High scores indicate better health-
related quality of life and functioning.  The SF-36 demonstrated good adequate internal 
consistency on each of the 8 dimensions.  SF-36 scores can be divided into two subscales.  One 
is referred to as the ―mental component‖ (SF-36 MC) and the other is referred to as the ―physical 
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component‖ (SF-36 PC). Cronbach’s α ranged from .73 (social functioning) to .96 (role 
limitations and vitality) (Brazier et al., 1992).  
Clinical Global Impression- Improvement scale (CGI-I; Guy, 1976).  The CGI-I is a 
commonly used single item index used to quantify improvement or worsening of anxiety 
symptoms since baseline (See Appendix D).  Participants are rated on a scale from 1 to 7, where 
1= very much improved, and 7= very much worse, based on a synthesis of patient’s subjective 
report of improvement, change in measures, and clinician’s report.  In a study of the clinical 
utility of CGI-I scores for evaluating psychiatric in-patients with a wide range of diagnoses, 
investigators found CGI-I scores were found to be correlated with other measures of clinical 
change (r=.71), indicating clinical utility and sensitivity to change (Berk et al., 2008).   Zaider, 
Heimberg, Fresco, Schneier, and Lebowitz (2003) also found evidence supporting the validity of 
the CGI-I as a meaningful measure of improvement in a sample of adults receiving treatment for 
social anxiety.  Zaider and colleagues (2003) found CGI-I scores to be correlated with both self-
report and clinician rated measures of social anxiety, disability, and quality of life at post 
treatment.   
  Salivary Cortisol- Baseline samples of salivary cortisol were taken 6 times a day over 2 
days before participants entered treatment because cortisol levels fluctuate throughout the day.  
Follow up samples were taken 6 times a day over the 2 days before participants’ week 12 visits.  
Samples were taken immediately at wakening, 30 minutes after wakening, noon, 3:00 pm, 6:00 
pm, and before bedtime.  Participants were instructed to not eat or drink anything other than 
water for half an hour before taking a sample and to refrain from drinking alcohol for two days 
prior to taking samples, and during the sampling period.  Participants tracked the exact time at 
which they took each sample on a diary form.  Samples were stored at -80 C until they 
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centrifugation.  Samples were centrifuged using an enzyme immunoassay kit (Salimetrics, State 
College, PA).  Cortisol levels and diurnal cycles were plotted.  Numerous studies have indicated 
that cortisol may be a biomarker for psychological distress in older adults (Luz et al., 2003; Ryff 
et al., 2006; Mantella et al., 2008). 
Procedure 
After participants were screened, those who were eligible were invited back for a baseline 
visit.  Two days prior to the baseline visit, participants collected samples of salivary cortisol.  At 
the baseline visit, participants completed measures of anxiety (the Structured Interview Guide for 
the Hamilton Anxiety Rating Scale; SIGH-A), worry (the Penn State Worry Questionnaire; 
PSWQ), and quality of life (the Short Form 36; SF-36) as part of a more extensive battery.  
Participants were randomly assigned to either a starting dose of 10 mg of escitalopram, or a 
placebo.   
Both participants and investigators were blinded to this assignment.  Participants received 
weekly follow up assessments for the first 4 weeks, when they received another SIGH-A, a 
measurement of side-effects, and a rating of global improvement, based on both clinician and 
participant impressions of change since baseline.  After 4 weeks, participants were eligible to 
receive an increased dose of escitalopram (20 mg).  All participants were eligible for a titrated 
dose, unless they received a CGI score of ―much improved‖ or higher, and a 40% or greater drop 
in SIGH-A score from baseline.  Between week 4 and week 12, participants were assessed either 
in person or by phone every 2 weeks.   
After 12 weeks, participants ended the blinded phase of the study, and were offered open 
label escitalopram for another 12 weeks.  For two days before the week 12 visit, participants 
collected follow up samples of salivary cortisol.  At the week 12 visit, participants completed 
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follow up measures, including the SIGH-A, PSWQ, and SF-36, as part of a more extensive 
assessment battery.  The current study examined data at baseline and week 12 in order to see how 
baseline variables predict change after a sufficient course of medication. 
 
Results 
Descriptive statistics were calculated for the demographic data from the group with a 
primary diagnosis of GAD and control participants (see Table 3). Descriptive statistics were also 
calculated for both participants with GAD and those without fir baseline levels of the outcome 
variables: PSWQ, SF-36 (mental and physical components), and salivary cortisol (see Table 4). 
Salivary cortisol levels were reported as an area under the curve value, and were calculated using 
the technique established in the literature (Mantella et al., 2008; Pruessner et al., 1997).  Skew 
and kurtosis were within one standard score from zero for all outcome variables with the 
exception of the MOS-Physical Component, which had a z-score for kurtosis of -1.105. The data 
were not transformed.  For participants with GAD who were randomized to medication, paired 
sample t-tests were conducted to determine whether the outcome variables differed significantly 
at week 12 from baseline (See Table 5). 
Baseline scores were significantly positively correlated with week 12 scores for the 
PSWQ, r(68) = .80, p < .001; the SF-36 MC, r(68) = .52, p < .001; and the SF-36 PC, r(68) = 
.79, p < .001(See Table 6).  However, these scores are not independent.  There were no 
significant correlations between baseline AUC levels of salivary cortisol or week 12 AUC levels 
and any other outcome variables. Because the CGI-I score assesses improvement from baseline, 
no baseline CGI-I scores were collected.  PSWQ week 12 scores were significantly correlated 
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with all outcome measures, with the exception of salivary cortisol.  Neither baseline nor week 12 
levels of salivary cortisol were correlated with any other outcome variable. 
A series of exploratory t-tests were performed to examine differences between the total 
group of those with a primary diagnosis of GAD (n=177) and the control group on the 14 
individual cluster scores of the SIGH-A measures.  All items differed significantly between the 
two groups (see Table 78).  
Hypothesis Testing 
The first objective was to determine which SIGH-A cluster symptoms were best at 
differentiating older adults with GAD from those without GAD.  To test this objective, a 
discriminant function analysis was performed to determine which cluster item baseline scores 
classified participants according to group membership.  Baseline scores on each of the 14 
symptom clusters of the SIGH-A were entered into the equation,  The discriminant analysis 
revealed one discriminant function, which included the ―Anxious Mood‖ and ―Tension‖ items 
from the SIGH-A, and correctly classified 100% of the participants as either ―GAD‖ or ―no 
GAD‖ (See Table 8), canonical R2 = .95 (λ = 0.1, χ2(2), p<.01) . 
A correlation matrix was constructed to examine the relations  between the predictor 
variables (―Anxious Mood‖ and ―Tension‖ items)  and baseline and week 12 scores on each of 
the outcome measures:  PSWQ, SF-36 MC, SF-36 PC, CGI-I, and AUC of salivary cortisol (see 
Table 6).  The ―Anxious Mood‖ item was significantly correlated with PSWQ scores at both 
baseline, r(68) = .32, p < .001, and week 12, r(68) = .24, p < .01, and it was inversely correlated 
with MOS MC scores at week 12, r(68) = -.24, p < .01.   
 The second objective was to determine how well the variables that best discriminate 
between older adults with GAD and those without GAD predict improvement across a variety of 
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measures.  To test the second objective, the ―Anxious Mood‖ and ―Tension‖ items were retained 
for use in a linear regression to predict which symptom presentations predicted response across 
outcome measures assessing different domains of treatment response (see Table 9).  Five 
hierarchical regression analyses with forward variable entry were completed, using different 
outcome measures as the dependent variable for each analysis:  worry level (as measured by the 
change in PSWQ score from baseline to week 12 of treatment), quality of life (as measured by 
the SF-36 Mental and Physical components change in from baseline to week 12 of treatment), 
clinical global improvement (as measured by the CGI-I), and salivary cortisol levels (as 
measured by change in salivary cortisol levels from baseline to week 12).  To account for 
baseline symptoms, baseline scores of the PSWQ, the SF-36 MC and PC, and salivary cortisol 
were entered into the first step of their respective regression analyses.  Baseline ―Anxious Mood‖ 
and ―Tension‖ SIGH-A item scores were added in the second step, using the backward entry 
method.  Because the CGI-I measures change from baseline, it was not necessary to account for 
baseline scores when examining the predictive value of the SIGH-A items on week 12 CGI-I 
score.  To perform a regression analysis for CGI-I, both the ―Anxious Mood‖ and ―Tension‖ 
items were added to the model using backwards entry.   
Two models were shown to predict week 12 PSWQ scores proved to be significant (See 
Table 9).  In the first model, only baseline PSWQ scores  were included, β = .79, t(66) = 
10.80, p < .001.  Baseline PSWQ scores accounted for a significant amount of the variance in 
week 12 scores, R2 =  .65, F(1,64) = 116.70, p < .01.  The ―Anxious Mood‖ nor the ―Tension‖ 
items of the SIGH-A at baseline were added to the second model, but this equation did not 
account for a significant amount of variance beyond that accounted for by baseline PSWQ 
scores.   
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There were also two models shown to predict week 12 SF-36 MC scores.  The first model 
only included baseline SF-36 MC scores, and it was significant, β = .52, t(66) = 4.96, p < .001.  
Baseline SF-36 MC scores predicted 28% of the variance in week 12 scores, ΔR2 =  .28, F(1,64) 
= 24.61, p < .001.  In the second model, the ―Anxious Mood‖ and ―Tension‖ items were added, 
but they did not account for a significant amount of variance beyond baseline scores. 
 A regression analysis was also conducted to see which variables predicted week 12 SF-
36 PC scores.  Again, two models were computed.  In the first model, only SF-36 PC scores were 
added, β = .79, t(66) = 10.31, p < .001.  Baseline SF-36 PC scores accounted for 62% of the 
variance in week 12 scores, R2 = .62, F(1,64) = 106.38, p < .001.  In the second model, but the 
―Anxious Mood‖ and ―Tension‖ SIGH-A items were added to the equation, but they did not 
account for significant variance beyond the baseline levels.    
Two models were tested for their ability to predict week 12 AUC measurements of 
salivary cortisol, but neither was significant.  The first model only included baseline levels of 
AUC, β = .30, t(66) = 1.39, p =.18.  Baseline AUC measurements accounted for 9% of the 
variance in week 12 scores, R2 = .09, F(1,64) = 1.94, p = .18.  The second model included the 
―Anxious Mood‖ and ―Tension‖ items, but still did not account for a significant amount of 
vaiance, R2 =  .12, F(1,64) = .85, p = .49.   
Similarly, the model were tested for its ability to predict week 12 CGI-I scores, was not 
significant.  The ―Anxious Mood‖ and ―Tension‖ items predicted only 0.8% of the variance in 
CGI-I score at week 12, R2 = .008, F(1,64) = 0.26, p = .78.   Residualized change scores were 
calculated for the PSWQ, the SF-36 MC and PC, and AUC for salivary cortisol as an alternative 
approach to characterizing outcome.  Residualized change scores are sometimes used as a way to 
measure change that accounts for both the size and the reliability of the change (MacKinnon, 
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2008).  Using the residualized change scores as criterion variables, the ―Anxious Mood‖ and 
―Tension‖ items were entered into a regression analysis using the forward entry method to 
determine whether they could predict residualized change scores for the measures discussed 
above.  No models were significant.   
Discussion 
The current study aimed to determine the extent to which baseline SIGH-A symptom 
clusters could predict treatment response across a variety of domains.  The investigator chose to 
examine the predictive value of symptoms clusters that best differentiated older adults with GAD 
from those without.   Though there has been debate about the ways in which anxiety differs in 
older adults (Christensen et al., 1999; Spar & LaRue, 1990), in the current study, anxious mood 
and tension best differentiated between groups of older adults with GAD and those without.  
Older adults with GAD had higher levels of each of the symptom clusters measuring physical 
symptoms of anxiety than those without GAD, but anxious mood and tension seemed to be key 
symptoms for distinguishing between the two groups.  These findings partially replicate the 
findings by Wetherell and colleagues (2003).  Wetherell and colleagues examined the diagnostic 
symptoms of GAD derived from the ADIS.  Using a discriminant function analysis, they found 
that distress and impairment, frequency and uncontrollability of worry, muscle tension, and sleep 
disturbances differentiated the groups, suggesting that they may be  key symptoms of late-life 
GAD.  Both the current study, and the study conducted by Wetherell and colleagues found that 
worry and tension differentiated between groups of older adults with GAD and those without.  
However, the Wetherell study examined different characterizations of worry, specifically 
frequency and uncontrollability, and distress and impairment.  Moreover, they found that sleep 
disturbances also differentiated between the groups.  The current study derived symptom clusters 
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for the analysis from the SIGH-A, while Wetherell and colleagues derived symptom clusters 
from the ADIS.  Though there is some overlap in the construct measured, the manner in which 
the questions were asked, and the range of symptoms measured differed between the current 
study and the study conducted by Wetherell and colleagues.  The SIGH-A covers a broader range 
of symptoms, including both diagnostic criteria, and other common anxiety symptoms.  These 
differences in measurement could account for the partial differences in results.   
The results of the discriminant function analysis support the idea that worry and tension 
are the hallmark symptoms of GAD in older adults.  Moreover, the finding that ―Anxious Mood‖ 
and ―Tension‖ were best able to classify older adults with GAD falls into line with the proposed 
DSM-V criteria for GAD, which proposes that we put more emphasis of excessive worry and 
tension for the diagnosis of GAD (APA, 2010).  Considering the conflicting findings in the 
literature as to whether older adults present with more somatic symptoms, this shift could 
simplify diagnosis of GAD in older adults.   
The finding that week 12 PSWQ scores, which reflect worry, were significantly 
correlated with global improvement and both physical and mental components of a measure of 
quality of life, provides further support for a greater focus on worry and tension for assessing 
GAD.  Week 12 PSWQ scores were significantly correlated with all outcome measures except 
salivary cortisol, adding support for convergent validity, and indicating the the PSWQ may be a 
good measure of GAD in older adults.   
Previous researchers have found significant correlations between severity of GAD as 
measured by the PSWQ, and the GADSS to be positively correlated with levels of salivary 
cortisol (Mantella et al., 2008).  It is unclear why the levels of salivary cortisol were not 
significantly correlated with any other outcome measure in this sample.   It is also unclear why 
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the model used to predict week 12 levels of salivary cortisol was non-significant.  It is possible 
that those who collected samples of salivary cortisol were qualitatively different than those who 
did not, though t-tests revealed that the group that collected both baseline and week 12 samples 
of salivary cortisol did not differ significantly according to age, sex, race, or years of education.  
However, because only a subsample of older adults collected salivary cortisol, the current study 
did not have enough power to test this outcome measure.   
Contrary to our predictions, scores on the ―Anxious Mood‖ and ―Tension‖ items of the 
SIGH-A at baseline did not significantly predict outcome in any domain.  Ratings of baseline 
levels of anxious mood or somatic tension did not significantly predict scores on outcome 
measures across different domains of response.  It is possible that the ―Anxious Mood‖ and 
―Tension‖ items measured constructs that are semantically similar to the outcome variables.  The 
―Anxious Mood‖ items assess for frequency, severity, and impairment as a result of anxiety or 
worry in the past week.  There could be overlap in the construct that the ―Anxious Mood‖ item 
and the PSWQ scale measured, as evidenced by the significant correlation between them.  The 
SF-36 MC and the ―Anxious Mood‖ and ―Tension‖ items were also correlated, indicating that 
the constructs measured may overlap.  As a result, it is possible that the SIGH-A items scores did 
not account for a significant amount of variance beyond baseline measures, because they were 
measuring similar things. 
Moreover, it is also possible that the fact that all participants met SCID criteria for GAD 
may have narrowed the range of presenting symptoms at baseline, and the severity of symptoms 
at baseline.  In order to meet diagnostic criteria for GAD, one must endorse excessive, 
distressing and difficult to control worry on more days than not.  All enrolled participants 
endorsed this type of worry in order to be eligible for the study.  Scores on the ―Anxious Mood‖ 
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item on the SIGH-A ranges from 0-4.  However, those who meet full criteria for GAD would 
likely automatically receive a score of 3 or 4 on the ―Anxious Mood‖ item because of the 
frequency and level of distress required to meet diagnostic criteria.  Possibly limited baseline 
variability in the sample on the ―Anxious Mood‖ item could result in the lack of ability to predict 
outcome on measures that have wider ranges of response.   
Further, baseline and week 12 scores on outcomes measures tended to be highly 
correlated (see Table 7), and thus accounted for much of the variability in outcome.  However, 
baseline scores on the PSWQ were very strong predictors of outcome at 12 weeks on the PSWQ.  
Similarly, baseline scores on the SF-36 PC were very stong predictors of week 12 SF-36 PC 
score.  Baseline scores on the SF-36 MC were also strong predictors of week 12 SF-36 MC.  
These findings indicate that higher scores on the PSWQ, the SF-36 PC, and the SF-36 MC at 
baseline are associated with higher scores on each respective measure after 12 weeks of 
pharmacotherapy.  It is difficult to make direct comparisons with other studies examining 
predictive value of symptoms because no other studies have used SIGH-A symptom clusters to 
predict treatment outcome.  However, we can draw some tentative comparisons to the literature.  
The present findings may support the findings of Haby and colleagues (2006), who found that 
greater severity of symptoms at baseline predicted poorer outcomes on measures of anxiety 
symptoms and health related quality of life.  However, they conflict with the findings of 
Wetherell and colleagues (2005), who reported that greater severity of GAD, as measured by the 
ADIS at baseline, predicted better outcomes on a reliable change index. This calls into question 
whether results obtained through different methods of measurement, and defined in different 
terms, can be generalized to the current study. The discrepancy could be due, in part, to 
differences in defining ―improvement‖ across treatment studies.  The current study defined 
27 
 
improvement as a multifaceted change that took place across multiple domains.  Improvement 
can be a reduction in worry, improvement in quality of life, global improvement, or reduction in 
levels of salivary cortisol.  However, other treatment studies have used different definitions of 
improvement.  Again, because different predictors and outcome measures and were used in the 
literature, comparisons to existing studies should be interpreted with caution. 
Limitations 
The current study was limited by the characteristics of the sample.  It examined a 
population of treatment-seeking older adults who enrolled in a pharmacotherapy study.  It is 
possible that these results may not generalize to other populations of older adults with GAD.  
Moreover, the study sample may be qualitatively different as a result of the inclusion and 
exclusion criteria (e.g., all those with substance abuse in the past 6 months were excluded) used 
for study eligibility. Further, a smaller sample of older adults with GAD collected salivary 
cortisol sample.  It is possible that those who collected the samples were qualitatively different 
than those who did not.  The small sample size may have resulted in insufficient power, limiting 
the findings.  
Several methodological factors may limit the findings of the current study.  This study 
aimed to determine which symptoms were best at differentiating older adults with GAD from 
those without GAD, and to see how those symptoms predicted response across different outcome 
measures.  However, in doing so, the investigators only examined the predictive value of the 
symptoms that were best at differentiating older adults with GAD from those without and did not 
examine the predictive value of other presenting symptoms.  Though examining the symptoms 
that are best at differentiating the two groups may make the results more clinically accessible, it 
is possible that symptoms that were less successful at differentiating between older adults might 
28 
 
be better predictors of outcome.  Moreover, the predictor variables used were single item 
responses, with a limited range.  Because of the limitations of using a single-item predictor 
variable with limited range, researchers might revisit the predictive value of anxious mood and 
tension using more comprehensive measures designed to assess the constructs, rather than single-
item scores.   
The current study was also limited in its ability to measure change.  There has been 
considerable controversy in the literature over the years regarding  the most appropriate ways to 
measure change (e.g., Cronbach & Furby, 1970).  Rogosa, Brandt, and Zimowski (1982) outlined 
some of the difficulties in measuring change.  They discussed the established finding that initial 
and outcome values tend to be correlated when measures are reliable.  These correlations can 
make assessing for clinically significant change difficult. A conservative approach to measuring 
change was taken in the present study, but it may have missed clinically significant change that 
was masked because of high correlations between baseline and outcome scores.  Moreover, 
without a control comparison, the current study could not account for the waxing and waning of 
anxiety over the 12 weeks of treatment.  The current study was also limited in its ability to assess 
for treatment compliance.  The investigators did not account for whether participants were taking 
their medication as prescribed when assessing outcome.   
Future Directions and Conclusions 
 The current study found that anxious mood and tension were the most salient symptoms 
in differentiating older adults with GAD from those without.  This suggests that measures used to 
assess GAD in late life should focus on tension and anxious mood.  The PSWQ was significantly 
correlated with other measures of outcome, and seems to be an appropriate assessment of late life 
GAD.  These results are in line with the proposed criteria for the DSM-V.   Though neither 
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baseline levels of anxious mood nor tension significantly predicted outcome in a variety of 
measures, baseline scores on the PSWQ, SF-36 MC and SF-36 PC were strong predictors of 
week 12 scores, with higher levels at baseline being associated with higher levels at week 12 on 
all measures.  Though these findings did not support our hypothesis that presenting symptoms 
could predict outcome, they still inform expectations for treatment.  
 Based on these findings, researchers might consider using more comprehensive measures 
of anxious mood and tension to examine their predictive value on outcome.  Researchers might 
also explore the predictive ability of other symptom presentations, including the other 12 
symptom clusters from the SIGH-A.  
 Further, it would be interesting to examine longer-term outcomes.  Do certain symptoms, 
or baseline severity measures, predict stable improvement?  Do other symptoms or severity 
measures predict relapse?  By learning the answers to these questions, providers could tailor 
treatments for GAD to individuals who are likely to receive the most benefit.   
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Table 1 
 
 
Predictor Variables and Treatment Outcome Measures for Pharmacological Interventions 
 
Researchers N Predictors Non Predictors Outcome 
Variable(s) 
 
Pollack et al., 
2003 
 
 
N=1,839 
(pooled data) 
 
Sleep disturbance 
predicted positive 
outcomes in both 
active treatment and 
placebo groups.  
Restlessness 
predicted poorer 
outcomes for both 
groups.  Trouble 
concentrating and 
history of substance 
abuse predicted 
better short-term 
outcomes for 
placebo group 
 
 
Age, duration 
of episode, 
benzodiazepine 
use, history of 
depression, 
history of 
panic disorder, 
fatigability,  
irritability, 
muscle 
tension, and 
number of 
GAD 
diagnostic 
criteria 
endorsed 
 
Reduction in 
HAM-A 
DeMartinis, 
Rynn, Rickels, & 
Mandos, 2000 
 
N= 735 Poorer prognosis 
associated with 
recent 
benzodiazepine use 
Prior 
benzodiazepine 
use, no 
benzodiazepine 
use 
 
Reduction in 
HAM-A 
CGI 
Patient attrition 
 
Rynn, Khalid-
Khan, Garcia-
Espana, Estemad, 
& Rickels, 2006 
N=396 Better outcomes 
were associated 
with early reduction 
in HAMA (baseline 
to weeks 1 and 2) 
*** Reduction in 
HAM-A at the 
end of the trial 
CGI 
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Table 2 
 
Predictor Variables and Treatment Outcome Measures for Psychosocial Interventions 
 
Researchers N Predictors Non Predictors Outcome 
Variable(s) 
 
Seivewright, 
Tyrer, & 
Johnson, 1998 
 
 
210 
psychiatric 
outpatients 
 
Poorer prognosis 
predicted by older 
age, presence of 
personality 
disorder at 
baseline, and the 
presence of a 
general neurotic 
syndrome at 
baseline  
 
 
Sex, marital status, 
social class, treatment 
randomization group, 
DSM-III diagnosis at 
baseline, duration of 
symptoms, single or 
recurrent episodes, 
life stress, baseline 
total scores on a 
measure of general 
psychopathology, 
depression scores, 
anxiety scores, 
number of comorbid 
symptoms 
 
 
Health service 
utilization 
Haby, 
Donnelly, 
Corry & Vos, 
2006 
 
Pooled 
data 
Poorer outcomes 
were associated 
with inclusion of 
greater severity at 
baseline, presence 
of a waitlist 
control group 
instead of an 
attention control. 
 
Treatment type, year 
of study, length of 
trial, country of 
study, language and 
number of dropouts 
from the control 
group 
 
Symptom 
levels, 
 Functioning 
Health-related 
quality of life 
measures 
 
Durham, 
Allan, & 
Hackett, 1997 
N=80 Being married 
was associated 
with better 
outcomes, and 
marital tension 
predicted poorer 
outcomes.  
Presence of other 
Axis I diagnoses 
predicted poorer 
outcomes. 
Screening variables, 
referral variables 
Sustained 
improvement, 
relapse and no 
consistent 
change 
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Wetherell et 
al., 2005 
N= 65 Better outcomes 
were associated 
with higher GAD 
severity at 
baseline, presence 
of Axis I 
comorbidity, and 
more frequent 
homework 
Age, gender, 
ethnicity, education, 
work status, duration 
of episode, sessions 
attended 
Reliable 
change indices 
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Table 3 
Demographic and Participant Characteristics by Diagnosis 
 GAD (N = 177) Control (N= 41) 
Age 
     Mean 
     SD 
     Range 
 
71.58 
7.74 
60 - 89 
 
75.12 
6.26 
62-88 
Gender 
     Male (%) 
     Female (%) 
 
32.3 
66.1 
 
33.3 
66.7 
Education (years) 
     Mean 
     SD 
     Range 
 
13.86 
2.90 
2-20 
 
14.48 
2.87 
7-20 
Marital 
     Never Married (%) 
     Married (%) 
     Separated 
     Divorced (%) 
     Widowed (%) 
     Cohabitating (%) 
 
 
9.4 
52.6 
1.8 
12.3 
22.8 
1.2 
 
 
7.9 
68.4 
2.6 
7.9 
13.2 
0.0 
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Table 3 (continued) 
  
Ethnicity 
     Caucasian (%) 
     African American (%) 
     Asian Pacific (%) 
 
81.9 
17.5 
           0.6 
 
92.9 
7.1 
0.0 
Job Status 
     Disabled (%) 
     Working Full Time (%) 
     Working Part Time (%) 
     Homemaker (%) 
     Unemployed (%) 
     Retired (%) 
 
 
5.3 
7.6 
9.4 
8.2 
6.4 
63.2 
 
 
0.0 
2.6 
5.3 
5.3 
0.0 
86.8 
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Table 4  
Means for Outcome Measures for all participants with GAD at Baseline 
 GAD 
Measure M SD 
PSWQ 51.86 15.96 
SF-36 MC 44.89 10.86 
SF-36 PC 42.65 10.64 
Salivary Cortisol (AUC) 29.25 10.69 
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Table 5 
 
Group differences for outcome measures at baseline and week 12 for participants with GAD who 
were randomized to medication 
 Baseline scores  Week 12 scores  
Outcome measure M SD  M SD t (138) 
PSWQ 54.29 12.46  47.76 12.30 .001** 
SF-36 MC 42.24 8.89  47.29 8.74 .001** 
SF-36 PC 39.72 11.16  39.85 11.48 .89 
Salivary cortisol (AUC) 29.43 10.91  25.72 12.79 .23 
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Table 6 
 
Correlations Between Baseline and Week 12 Administration of Predictor and Outcome Measures 
Measure 1 2 3 4 5 6 7 8 9 10 11 
1. PSWQ 
Baseline 
 
--         
  
2. PSWQ 
Week 12 
 
.80** --        
  
3. SF-36 
MC 
Baseline 
 
-.43** -.52** --       
  
4. SF-36 
MC 
Week 12 
 
-.16 -.45 .52** --      
  
5. SF-36 
PC 
Baseline 
 
.13 
 .29* -.27 -.08 --     
  
6. SF-36 
PC  
Week 12 
 
.18 .28* -.22 -.15 .79** --    
  
7. 
Salivary 
Cortisol 
AUC 
Baseline 
 
.32 .20 -.16 -.16 .26 .17 --   
  
8. 
Salivary 
Cortisol 
AUC 
Week 12 
 
.14 .19 -.25 -.15 .22 .03 .30 --  
  
9. CGI-I 
Week 12 
 
.15 .39** -.15 -.46** -.19 -.23 .19 .19 -- 
  
10. .32** .24* -.19 -.30* .01 .11 -.19 .12 -.05   
48 
 
―Anxious 
Mood‖ 
item 
Baseline 
 
 
-- 
11. 
―Tension‖ 
item 
Week 12 
.07 .04 -.24* -.07 -.12 -.17 .04 -.03 -.05 
 
 
.02 
 
 
 
 
-- 
*p<.01.  ** p<.001. 
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Table 7 
 
Differences Between SIGH-A Cluster Item Scores in the GAD and Control Group 
 
 GAD 
(n = 177) 
No GAD 
(n = 41) 
 
 
Symptom Cluster 
 
M 
 
SD 
 
M 
 
SD 
 
t (216) 
 
1. Anxious Mood 
 
3.01 
 
.34 
 
.34 
 
.53 
 
40.65** 
2.  Tension 2.70 .58 .29 .56 24.20** 
3.  Fears .59 .87 .02 .16 4.15** 
4.  Insomnia 2.76 .84 .98 1.06 11.62** 
5.  Concentration 1.77 .93 .49 .64 8.42** 
6.  Depressed 
Mood 
1.34 .92 0.00 0.00 9.41** 
7.  Somatic 
Muscular 
2.28 .98 .73 1.00 9.09** 
8.  Somatic 
Sensory 
1.49 1.12 .46 .64 6.19** 
9.  Cardiovascular .60 .86 .15 .48 3.27** 
10.  Respiratory 1.19 .96 .10 .30 7.24** 
11.  Gastro-
intestinal 
1.80 1.04 .68 .85 6.43** 
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12.  Genito-
urinary 
.91 1.14 .32 .88 3.12* 
13.  Autonomic 1.13 .99 .15 .48 6.21** 
14.  Interview 
Behavior 
1.41 .65 .08 .27 12.71** 
*p<.01.  ** p<.001. 
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Table 8 
 
Classification Results for Discriminant Function Analysis 
 
   Predicted group membership 
  GAD  No GAD 
Actual Group Membership n n %  n % 
GAD 41 41 100.0  0 0.0 
No GAD 177 0 0.0  177 100.0 
Note. Overall percentage of correctly classified cases = 100.0% 
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Table 9 
Regression Models for Predicting Outcomes of GAD Using SIGH-A Clusters as Predictors
Variable B SEB β R2 ΔR2 
PSWQ 
     Model 1 
    
.65** 
 
.65** 
          Baseline PSWQ .79 .07 .80** 
 
  
     Model 2    .65** .003 
          Baseline PSWQ .78 .08 .79   
          Baseline ―Anxious Mood‖ 2.36 4.58 .04   
          Baseline ―Tension‖ -.83 1.81 -.03   
SF-36 MC      
     Model 1    .28** .28** 
          Baseline SF-36 MC .52 .10 .52** 
 
  
     Model 2    .30** .03 
          Baseline SF-36 MC .50 .11 .51**   
          Baseline ―Anxious Mood‖ -6.24 4.41 -.15   
          Baseline ―Tension‖ .91 1.87 .05   
SF-36PC      
     Model 1    .62** .62** 
          Baseline SF-36 PC .81 .08 .79** 
 
  
     Model 2    .64** .02 
          Baseline SF-36 PC .80 .08 .78**   
          Baseline ―Anxious Mood‖ 5.58 4.11 .10   
          Baseline ―Tension‖ -1.63 1.73 -.07   
CGI-I      
     Model 1    .008 .008 
          Baseline ―Anxious Mood‖ -.17 .41 -.05   
          Baseline ―Tension‖ 
 
.13 .22 .07   
 
Salivary Cortisol AUC 
 
 
 
 
 
 
  
     Model 1    .09 .09 
          Baseline AUC 
 
.35 .25 .30   
     Model 2    .12 .04 
          Baseline PSWQ .39 .26 .34   
          Baseline ―Anxious Mood‖ 11.30 13.57 .19   
          Baseline ―Tension‖ -1.18 4.50 -.06   
*p<.01.  ** p<.001. 
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Appendix A 
Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) 
 The purpose of this interview guide is to assist in the reliable assessment of anxiety 
severity by standardizing the method of assessment and providing clear anchor points for the 
assignment of severity ratings.  The interview items and the anchor points are meant to 
supplement good clinical judgment, not replace it.  To ensure full assessment of the domain of 
inquiry for each item, the interviewer should ask all questions provided.  These defining 
characteristics are meant to aid in the reliable use of the severity scales; they represent examples 
of the severity levels appropriate to the rating,  Severity is defined most readily the frequency of 
occurrence, degree of distress and interference associated with the symptom.  The number of 
symptoms present is included in the severity rating only as it impacts on distress and 
interference.  For example, a higher rating may be achieved for a single severe symptom and for 
several mild to moderate symptoms.  Alternatively, several mild symptoms may lead to a 
moderate rating of severity because of their overall impact on distress.   
 
 In addition to the guidelines for each item, the interviewer should note the following 
conventions for boundary problems: 
 
A.  None to mild boundary:  Most questionable cases should be rated as one, as zero is 
meant to be an anchor point with no symptoms present. 
B. Mild to moderate boundary:  Symptoms are endorsed less than fifty percent of the 
time and cause little or no interference or distress; rate as one.  Symptoms are 
endorsed less than fifty percent of the time and are rated as causing mild to moderate 
interference or distress; rate as two.  Symptoms are endorsed more than fifty percent 
of the time and are rated as causing mild interference or distress; rate as two. 
C. Moderate to severe boundary:   Symptoms are endorsed less than fifty percent of the 
time and are rated as causing severe interference or distress; rate as three.  Symptoms 
are endorsed more than fifty percent of the time and are rated as causing moderate to 
severe interference or distress, but not both; rate as three. 
D. Severe to very severe boundary:  Questionable cases should generally be rated as 
three, ratings of four are reserved for behavioral events clearly identified by the rating 
anchors. 
 
To elicit information necessary for assigning severity ratings, the interviewer must assess the 
frequency of occurrence, degree of distress, and degree of interference associated with the 
symptoms.  The following questions are recommended for this assessment: 
 
A.  Have you have the symptom every day?  IF NO, Have you had the symptom more 
days than not? 
B. How much does the symptom bother you? 
C. How much does it interfere with your life? 
 
Starting the interview:  Begin the interview with an introduction, describing the scale and 
its purpose in a way that is relevant for the specific patient and for the specific assessment.  For 
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example, for the first administration, one might say, “As you know, we have diagnosed your 
condition as an anxiety disorder.  We are now going to be asking you a number of questions 
about different aspects of your anxiety.  Together, they allow us to rate as accurately as possible 
the overall severity of your anxiety state.  We will be rating anxiety severity in this way at 
different points in your treatment in order to decide how much the treatment is helping you.”  
This example is not meant as a script.  The interviewer should introduce the scale in a way most 
comfortable for the patient and for her/his own style. 
 
It is assumed that the interviewer has completed a previous diagnostic interview and is 
familiar with the patient’s general range of symptoms.  If this is not true, the interviewer should 
preface the Hamilton Anxiety Scale by asking for a summary (five or ten minutes) of the 
patient’s specific worries, disturbing physical symptoms, duration of the syndrome, and its 
characteristics over time (e.g. Does it tend to wax and wane, or has it been persistent since the 
onset?).  The interviewer should also obtain a global statement on distress and impairment during 
the last week, and the cause of this distress.  This information will provide the rater with a 
background or framework from which to conduct the ratings.   
 
Although there are differences between studies, it is assumed that all ratings for the 
Hamilton Anxiety Rating Scale for patients with panic disorder will focus exclusively on times 
other than panic episodes.  
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1.  Anxious Mood 
What’s your mood been like this 
week? 
Have you been feeling anxious? 
Nervous?  
Worrying? 
Feeling something bad may happen? 
Feeling irritable? 
 
0- No anxious mood 
 
1- Mild worry or anxiety indicated only on 
questioning; no change in functioning 
 
2- Preoccupation with minor events,  anxiety 
on as many days as not 
 
3- Nearly daily episodes of anxiety/ worry with 
disruption of daily activities; daily 
preoccupation 
 
 
4- Nearly constant anxiety; significant role 
disruption 
2. Tension 
Have you been feeling tense? 
Do you startle easily? 
     Cry easily? 
     Fatigue easily? 
Have you been trembling? 
Feeling restless? 
Unable to relax? 
 
0-  No tension 
 
1- Several days of mild tension or occasional 
(e.g., 1-2) episodes of exaggerated startle or 
labile mood 
 
2- Muscle tension or fatigue 50% of the time 
or repeated (>2) episodes of trembling, 
exaggerated startle, etc. 
 
3- Nearly daily muscle tension, fatigue and/or 
restlessness >75% of the time or persistent, 
disruptive symptoms 
 
4- Constant tension, restlessness, agitation, 
unable to relax in the interview 
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3.  Fears 
Have you been feeling fearful 
(phobic) of situations or events? 
For example, have you been 
afraid of the dark? 
Of strangers? 
Of being left alone? 
Of animals? 
Of being caught in traffic? 
Of crowds? 
Other fears? 
 
0-  No fears 
 
1- Mild phobic concerns that do not cause 
significant distress or disrupt functioning 
 
2- Fears lead to distress or avoidance on one or 
more occasions 
 
3- Fears are an object of concern on a near 
daily basis (75%); patient may need to be 
accompanied by others to a fearful event 
 
4- Fears or avoidance that markedly affect 
function. Patient may avoid multiple 
situations even if accompanied; extensive 
agoraphobia 
  
4.  Insomnia 
How have you been sleeping this 
past week? 
Any difficulties falling asleep? 
Any problems with waking 
during the night? 
Waking early and not being able 
to return to sleep? 
Do you feel rested in the 
morning? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-  No sleep disturbance 
 
1- Mildly disrupted sleep (e.g., one or two 
nights of difficulties falling asleep or 
nightmares) 
 
2- Several episodes of sleep disturbance that is 
regular but not persistent (e.g., over one-
half hour falling asleep, nightmares, or 
excessive AM fatigue) 
 
3- Persistent sleep disruption (on more days 
than not), characterized by difficulty falling 
asleep (e.g., over one half hour) or staying 
asleep, restlessness, unsatisfying sleep or 
frequent nightmares, or fatigue 
 
4- Nightly difficulties with sleep onset or 
maintenance, or daily severe fatigue on 
waking in the AM 
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5.  Concentration 
Have you had trouble 
concentrating? 
Remembering things? 
 
0-  No difficulties 
 
1- Infrequent episodes of forgetfulness or 
difficulty concentrating that are not 
distressing to the patient 
 
2- Recurrent episodes of forgetfulness or 
difficulty concentrating, or episodes of 
sufficient intensity to cause the patient 
recurrent concern 
 
3- Persistent concentration or memory 
impairment that interferes with daily tasks 
 
4- Significant role impairment due to 
concentration difficulties 
6.  Depressed Mood 
Have you been feeling depressed? 
Have you lost interest in things? 
Do you get pleasure from friends 
or hobbies? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-  No depression 
 
1- Occasional or mild blue or sad mood, or 
reports of decreased enjoyment of activities 
 
2- Sad or blue mood or disinterest 50% of the 
time, mood does not generally interfere with 
functioning 
 
3- Persistent depressed mood or loss of 
pleasure, mood is significantly distressing to 
patient, or may be evident to others 
 
4- Daily evidence of severe depression with 
significant role impairment 
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7.  Somatic Muscular 
Have you been experiencing any 
aches, pains, or stiffness in your 
muscles? 
Have you experienced any muscle 
twitching or sudden muscle jerks? 
Have you had an unsteady voice?  
 
0-  No muscular symptoms 
 
1- Infrequent presence of one or two 
symptoms, no significant distress 
 
2- Mild distress over several  
symptoms or moderate distress over a single 
symptom 
 
3- Symptoms occur on more days than not, 
symptoms are associated with moderate to 
severe distress and/or regular attempts at 
symptom control by limiting activities or 
taking medications 
 
4- Daily or near daily episodes of symptoms 
that cause the patient significant distress and 
lead to restriction of activities or repeated 
visits for medical attention 
8.  Somatic Sensory  
Have you been experiencing any 
ringing in your ears? 
Blurred vision? 
Hot or cold flashed? 
Feelings of weakness? 
Or prickling sensations? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-  No symptoms 
 
1- Infrequent presence of one or two 
symptoms, no significant distress 
 
 
2- Mild distress over several symptoms or 
moderate distress over a single symptom 
 
3- Symptoms occur on more days than not, 
symptoms are associated with moderate to 
severe distress and/or regular attempts at 
symptom control by limiting activities or 
taking medications 
 
4- Daily or near daily episodes of symptoms 
that cause the patient significant distress and 
lead to restriction of activities or repeated 
visits for medical attention 
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9.  Cardiovascular 
Have you had episodes of a 
racing, skipping, or pounding 
heart? 
How about pain in your chest? 
Fainting feelings? 
   
0- No symptoms 
 
1- Infrequent presence of one or two 
symptoms, no significant distress 
 
2- Mild distress over several symptoms or 
moderate distress over a single symptom 
 
3- Symptoms occur on more days than not, 
symptoms are associated with moderate to 
severe distress and/or regular attempts at 
symptom control by limiting activities or 
taking medications 
 
4- Daily or near daily episodes of symptoms 
that cause the patient significant distress and 
lead to restriction of activities or repeated 
visits for medical attention 
10.  Respiratory 
Have you been having trouble 
with your breathing? 
Any pressure or constriction in 
your chest? 
Choking feelings? 
Sighing? 
or Feeling like you can’t catch 
your breath? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
0- No symptoms 
 
1- Infrequent presence of one or two 
symptoms, no significant distress 
 
2- Mild distress over several symptoms or 
moderate distress over a single symptom 
 
3- Symptoms occur on more days than not, 
symptoms are associated with moderate to 
severe distress and/or regular attempts at 
symptom control by limiting activities or 
taking medications 
 
4- Daily or near daily episodes of symptoms 
that cause the patient significant distress and 
lead to restriction of activities or repeated 
visits for medical attention 
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11.  Gastro-intestinal 
Have you had any stomach pain 
or discomfort? 
Nausea or vomiting? 
Burning or rumbling in your 
stomach? 
Heartburn? 
Loose bowels? 
Constipation? 
Sinking feeling in your stomach? 
 
0-  No symptoms 
 
1- Infrequent and minor episodes of gastric 
discomfort, constipation, or loosening of 
bowel, fleeting nausea 
 
2- An episode of vomiting or recurrent 
episodes of abdominal pain, loosening of 
bowels, difficulty swallowing, etc. 
 
3- Symptoms more days than not that are very 
bothersome to the patient or lead to 
concerns over eating, bathroom availability, 
or use of medication 
 
4- Daily or near daily episodes of symptoms 
that cause the patient significant distress and 
lead to restriction of activities or visits for 
medical attention  
12.  Genito-urinary 
Have you been experiencing any 
urinary difficulties? 
For example, have you had to 
urinate more frequently than 
usual? 
Have you had more urgency to 
urinate? 
Have you had decreased sexual 
interest? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-  No symptoms 
 
1- Infrequent or minor urinary symptoms or 
mild changes in sexual interest 
 
2- Urinary symptoms several days during the 
week, occasional difficulties with sexual 
functioning 
 
3- Urinary or sexual symptoms more days than 
not 
 
4- Daily urinary or sexual symptoms that lead 
to distress and medical care seeking 
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13.  Autonomic 
Have you been experiencing any 
flushing in your face? 
Getting pale? 
Lightheadedness? 
Have you been having any 
tension headaches? 
Have you felt the hair rise on 
your arms, the back of your neck 
or head, as though something had 
frightened you? 
 
0-  No symptoms 
 
1- Mild symptoms that occur infrequently 
 
2- Symptoms occurred several times during the 
week and were bothersome 
 
3- Near daily symptoms with distress or 
embarrassment about the symptoms 
 
4- Daily symptoms that are a focus of distress 
and impair function (e.g. daily headaches or 
lightheadedness leading to limitation of 
activities) 
14.  Behavior 
Rate Interview Behavior 
Fidgeting, restlessness or pacing, 
tremor of hands, furrowed brow, 
strained face, sighing or rapid 
respirations, facial pallor, 
frequent swallowing, etc. 
 
0-  No apparent symptoms 
 
1- Presence of one or two symptoms to a mild 
degree 
 
2- Presence of several symptoms of mild 
intensity or one symptom of moderate 
intensity 
 
3- Persistent symptoms throughout the 
interview 
 
4- Agitation, hyperventilation, difficulty 
completing the interview 
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Appendix B 
Penn State Worry Questionnaire 
 
Enter the number that best describes how typical or characteristic each item is of you, 
putting the number next to the item. 
 
1  2  3  4  5 
  typical      typical     typical 
Not at all   Somewhat      Very 
 
 
______ 1. If I don’t have enough time to do everything, I don’t worry about it. 
______ 2. My worries overwhelm me. 
______ 3. I do not tend to worry about things. 
______ 4. Many situations make me worry. 
______ 5. I know I shouldn’t worry about things, but I just cannot help it. 
______ 6. When I am under pressure I worry a lot. 
______ 7. I am always worrying about something. 
______ 8. I find it easy to dismiss worrisome thoughts. 
______ 9. As soon as I finish one task, I start to worry about everything else I have to 
do. 
______ 10. I never worry about anything. 
______ 11. When there is nothing more I can do about a concern, I don’t worry about 
it anymore. 
______ 12. I’ve been a worrier all my life. 
______ 13. I notice that I have been worrying about things. 
______ 14. Once I start worrying, I can’t stop. 
______ 15. I worry all the time. 
______ 16. I worry about projects until they are done. 
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Appendix C 
 
SF-36 
1. In general, would you say your health is: 
Excellent Very Good Good Fair Poor 
1 2 3 4 5 
 
2. Compared to one year ago, how would you rate your health in general now? 
Much Better 
than one year 
ago 
Somewhat 
better now than 
one year ago 
About the same 
as one year ago 
Somewhat 
worse now than 
one year ago 
Much worse 
now than one 
year ago 
1 2 3 4 5 
 
3. The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
a.  Vigorous activities, such as running, lifting heavy objects, participating in 
strenuous sports 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, 
bowling, or playing golf 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
c. Lifting or carrying groceries 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
d. Climbing several flights of stairs 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
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e. Climbing one flight of stairs 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
f. Bending, kneeling, or stooping 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
g. Walking more than a mile 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
h. Walking several blocks 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
i. Walking one block 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
j.  Bathing or dressing yourself 
Yes, Limited a lot Yes, Limited a little No, Not Limited at all 
1 2 3 
 
4. During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health?   
a.   Cut down the amount of time you spent on work or other activities. 
Yes = 1  No = 0 
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b. Accomplished less than you would like 
Yes = 1  No = 0 
c. Were limited in the kind of work or other activities 
Yes = 1  No = 0  
d. Had difficulty performing the work or other activities (for example, it took 
extra effort) 
Yes = 1  No = 0 
5. During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
a.  Cut down the amount of time you spent on work or other activities 
Yes = 1  No = 0 
b. Accomplished less than you would like 
Yes = 1  No = 0 
c. Didn't do work or other activities as carefully as usual 
Yes = 1  No = 0 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups? 
Not at all Slightly Moderately Quite a bit Extremely 
0 1 2 3 4 
 
7. How much bodily pain have you had during the past 4 weeks? 
None Very Mild Mild Moderate Severe Very Severe 
0 1 2 3 4 5 
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8. During the past 4 weeks, how much did pain interfere with your normal work 
including both work outside the home and housework)? 
Not at all Slightly Moderately Quite a bit Extremely 
0 1 2 3 4 
 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the way 
you have been feeling. How much of the time during the past 4 weeks: 
a.  Did you feel full of pep? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
  
b.  Have you been a very nervous person? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
c.  Have you felt so down in the dumps that nothing could cheer you up? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
d.   Have you felt calm and peaceful? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
e.  Did you have a lot or energy? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
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f.  Have you felt downhearted and blue? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
g.  Did you feel worn out? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
h.  Have you been a happy person? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
i.  Did you feel tired? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
All of the 
time 
Most of the 
time 
Some of 
the time 
A good bit 
of the time 
A little of 
the time 
None of the 
time 
0 1 2 3 4 5 
 
11. How TRUE or FALSE is each of the following statements for you? 
a.  I seem to get sick a little easier than other people 
Definitely 
True 
Mostly True Don’t know Mostly false Definitely 
false 
0 1 2 3 4 
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b.  I am as healthy as anybody I know 
Definitely 
True 
Mostly True Don’t know Mostly false Definitely 
false 
0 1 2 3 4 
 
c.   I expect my health to get worse 
Definitely 
True 
Mostly True Don’t know Mostly false Definitely 
false 
0 1 2 3 4 
 
d.  My health is excellent 
Definitely 
True 
Mostly True Don’t know Mostly false Definitely 
false 
0 1 2 3 4 
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Appendix D 
 
 
Clinical Global Impression – Global Improvement (CGI –I) Scale 
 
Rate total improvement whether or not, in your clinical judgment, it is due entirely to 
drug treatment. 
 
 
   Compared to baseline, how much has he/she changed? 
 
  □  0 = Not assessed 
  □  1 = Very much improved 
  □  2 = Much improved 
  □  3 = Minimally improved 
  □  4 = No change 
  □  5 = Minimally worse 
  □  6 = Much worse 
  □  7 = Very much worse 
 
